Herbal Cascara sagrada may process a major bioactive compound targeted by the pharmaceutical companies for the development of a conventional medicine in the treatment of pancreatic cancer, some scientists suggested.
Primary pancreatic cancer is cancer that originates in the pancreas as the result of the alternation of DNA of the cell.
Most cases of pancreas cancer start in the cell on the surface of the inner lining tissue. However, as the cancer progress, the malignant cells of the pancreas, although unusual may travel a far distance away to infect other healthy tissue and organs.
The pancreas cancer was found to be the site of metastasis from renal cell cancer, lung, colon and breast cancers.
The herbal bark has been used in traditional medicine for gastrointestinal support. and it is thought to have a laxative and natural cleansing, etc., effect.
Besides the main compound of anthraquinones, other compounds of Cascara sagrada include anthraquinone glycosides, (emodin, frangulin, iso-emodin, aloe-emodin, and chrysophanol), rhein, aloin, malic acid, tannic acid, cascarosides A, B, C, and D, and hydroxy anthracene derivatives (HAD), etc.
In the reassessment of the effects of Emodin in inducing the apoptosis of pancreatic cancer cells and inhibiting the tumor growth, researchers at the Zhejiang University School of Medicine conducted an investigation to examine pathways activated by Emodin during the anti-pancreatic cancer process.
These results suggested that Emodin may be a potential anti-tumor effect on pancreatic cancer via apoptosis and suppression of angiogenesis.
* In Human pancreatic cancer cells SW1990, Emodin or their combination (gemcitabine plus emodin) induces cellular proliferation and apoptosis.
* Emodin or emodin plus gemcitabine downregulated the expression of XIAP and NF-κB similar to above study, compared to the control group in vitro
* The combination of emodin and gemcitabine showed the more significant reduction in the T/NT ratio, an indication of the risk of cancer onset, SUV, an indication on the response to cancer treatment and tumor weight compared to monotherapy.
* Emodin enhanced tumor apoptosis induced by gemcitabine in vivo.
These results suggested that Emodin enhances the antitumor effect of gemcitabine in SW1990 pancreatic cancer in vitro and in vivo by downregulation of NF-κB expression, thus inhibiting the expression of XIAP.
Further data collection large example size and multi-centers studies performed with human consumption of the whole food or its bioactive compounds during the course of the disease will be necessary to complete the picture of herbal Cascara sagrada anti-pancreatic cancer possibilities.
How To Get Rid Of Eye Floaters
Contrary To Professionals Prediction, Floaters Can Be Cured Naturally
Ovarian Cysts And PCOS Elimination
Holistic System In Existence That Will Show You How To
Permanently Eliminate All Types of Ovarian Cysts Within 2 Months
Back to Kyle J. Norton Homepage http://kylejnorton.blogspot.ca
Kyle J. Norton (Scholar, Master of Nutrition, All right reserved)
Health article writer and researcher; Over 10.000 articles and research papers have been written and published online, including worldwide health, ezine articles, article base, health blogs, self-growth, best before it's news, the karate GB daily, etc.,.
Named TOP 50 MEDICAL ESSAYS FOR ARTISTS & AUTHORS TO READ by Disilgold.com Named 50 of the best health Tweeters Canada - Huffington Post
Nominated for shorty award over last 4 years
Some articles have been used as references in medical research, such as international journal Pharma and Bioscience, ISSN 0975-6299.
(1) Antitumor activity of emodin against pancreatic cancer depends on its dual role: promotion of apoptosis and suppression of angiogenesis by Lin SZ, Wei WT, Chen H, Chen KJ, Tong HF, Wang ZH, Ni ZL, Liu HB, Guo HC, Liu DL. (PubMed)
(2). Enhanced antitumor efficacy by the combination of emodin and gemcitabine against human pancreatic cancer cells via downregulation of the expression of XIAP in vitro and in vivo by Wang ZH, Chen H, Guo HC, Tong HF, Liu JX, Wei WT, Tan W, Ni ZL, Liu HB, Lin SZ.(PubMed)(3). [Pancreatic cancer and lifestyle factors].[Article in Czech] by Azeem K1, Sevčíková J, Tomášková H, Horáková D, Procházka V, Martínek A, Shonová O, Janout V, Kollárová H. (PubMed)